首页 > 

    wهjz6۫tOu3cw$O[?®b=!>%ewQ~TfD1OYYoϧ?|‚eIVOکͧ5Z/NʴXYן97MpmGTאVl08%p‰Jl 2025-01-26

    wهjz6۫tO�u3cw$O[?®b=!>%ewQ~TfD1OYYoϧ?|‚eIVOکͧ5Z/NʴXYן97MpmGTאVl08%p‰Jl<B<EPj<Sr&0aX ʚPKS1':6Ͻy=7M|z ̩K�G{+oލ)3N<|5ZoE^EPN(.҅Wˆ+dD{awهjz6۫tOu3cw$O[?®b=!>%ewQ~TfD1OYYoϧ?|‚eIVOکͧ5Z/NʴXYן97MpmGTאVl08%p‰JlBy HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case and was written by D. John Sauer, Trump’s choice for solicitor general. The argument submitted to the court is the latest example of Trump inserting himself in national issues before he takes office. The Republican president-elect has already begun negotiating with other countries over his plans to impose tariffs, and he intervened earlier this month in a plan to fund the federal government, calling for a bipartisan plan to be rejected and sending Republicans back to the negotiating table. He has been holding meetings with foreign leaders and business officials at his Mar-a-Lago club in Florida while he assembles his administration, including a meeting last week with TikTok CEO Shou Chew. Trump has reversed his position on the popular app, having tried to ban it during his first term in office over national security concerns. He joined the TikTok during his 2024 presidential campaign and his team used it to connect with younger voters, especially male voters, by pushing content that was often macho and aimed at going viral. He said earlier this year that he still believed there were national security risks with TikTok, but that he opposed banning it. The filings Friday come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. The law was was signed by President Joe Biden in April after it passed Congress with broad bipartisan support. TikTok and ByteDance filed a legal challenge afterwards. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.” In their brief to the Supreme Court on Friday, attorneys for TikTok and its parent company ByteDance argued the federal appeals court erred in its ruling and based its decision on “alleged ‘risks’ that China could exercise control” over TikTok’s U.S. platform by pressuring its foreign affiliates. The Biden administration has argued in court that TikTok poses a national security risk due to its connections to China. Officials say Chinese authorities can compel ByteDance to hand over information on TikTok’s U.S. patrons or use the platform to spread or suppress information. But the government “concedes that it has no evidence China has ever attempted to do so,” TikTok’s legal filing said, adding that the U.S. fears are predicated on future risks. In its filing Friday, the Biden administration said because TikTok “is integrated with ByteDance and relies on its propriety engine developed and maintained in China,” its corporate structure carries with it risk.For years, school bus driver Herman Cruse would drop off Middle Township, New Jersey, students in the morning and then find ways to pass the time until his next run to pick them up at the end of the school day. Cruse lives too far from the school district to return home between routes, and he wanted to do something more meaningful than running errands, working out or napping between shifts. Overhearing one of the kindergartners on the bus talking about troubles with a reading assignment, Cruse approached the student’s teacher at Middle Township Elementary School No. 1 in Cape May Court House to ask if he could help. It was 2021, and Alex Bakley had Cruse meet with the student to read. The two connected, and word spread at the sprawling school. Other students and teachers requested reading time with Cruse. “It caught on quickly,” said Cruse, 56. “It took on a life of its own.” Since he started reading to that first boy three years ago, Cruse estimates that he has read with hundreds of students, mostly kindergartners and first graders. The students have been dubbed “Mr. Herman’s Kids,” and they view Cruse as a beloved mentor, role model and father figure. Some ride the yellow school bus Cruse drives. “He’s not just picking up kids,” said Principal Chris Paskalides. “He’s just taken it to another level. He really cares about the kids.” A section in the kindergarten wing has been designated as “Mr. Herman’s Kids Corner.” Sitting at a round table, Cruse reads with students one-on-one for about 20 to 30 minutes during their school day three times a week. Students may select a title from a bookshelf stocked by Cruse or a book from their classroom. On a recent morning, Cruse had about 2 1⁄2 hours between shifts and reported for his reading assignments. Cruse listened patiently as Octavia Hebron, 6, read aloud from “I’m Thankful Each Day.” He gently offered assistance when she stumbled over a word, encouraging her to sound it out as she followed with her finger. “Good job! Awesome!” Cruse told her, giving her a high-five. Cruse recruited another bus driver, Dan O’Connell, 70, to help with reading to reach more students. Both men voluntarily use their downtime for reading with students. The school has about 700 students in pre-K through second grade. Sitting on a mini-size chair across the room from Cruse, O’Connell read to students or let them read to him. He chuckled when 5-year-old Melody Roberto-Hammond wanted to read a second book. “We’re not reading them all,” O’Connell told her. “Maybe next time.” Experts say reading helps with language comprehension, vocabulary building and story structure. With Cruse, reading also acts as a relationship-building activity, particularly important with a male role model when most children are exposed to female teachers in lower grades, said Valarie G. Lee, an associate professor in the critical literacy, technology, and multilingual education department at Rowan University. “I think what they’re doing is wonderful. The evidence is in kids wanting to read with him,” Lee said. “Building that foundation early on is really critical.” Veteran teacher Linda Bakley said Cruse has a special knack with students. Sometimes they ask to read with him instead of her, she said, laughing. Some of them refer to Cruse as “Pop Pop.” “This man is loving and caring. The kids feel it,” Linda Bakley said. “The kids do adore him. When they say it takes a village, he is the village.” Cruse reinforces skills that students learn in the classroom, and he questions them about what they’ve read to build comprehension, Bakley said. He also asks how they are doing outside of school, which has built their trust, she said. A grandfather and father of five adult children, Cruse said he became an avid reader at a young age. His mother purchased an encyclopedia set for the family, and he devoured the reference books, along with books, maps and atlases, he said. “I read pretty much everything I could put my hands on,” he recalled. Cruse passed on that love of reading to his own children. He applies the same approach to the students at Middle Township. “I want to nurture every gift these children are exuding in these classrooms,” he said. “Whatever they learn from me, whatever they get, I hope they just go further, do more and be more as they grow.” Get local news delivered to your inbox!



    Review: Colin Firth stars as Dr. Jim Swire in ‘Lockerbie: A Search for Truth’ on Peacock

    The Sacramento Kings have fired coach Mike Brown less than halfway through his third season with the team mired in a five-game losing streak, a person familiar with the decision told The Associated Press. The person spoke on condition of anonymity Friday because the firing hadn't been announced by the team. ESPN first reported the firing. Brown won NBA Coach of the Year in his first season in 2022-23, when he helped Sacramento end the longest playoff drought in NBA history at 16 seasons. But Sacramento lost in the play-in tournament last year and was off to a 13-18 start this season, leading to the move to fire Brown about six months after he agreed to a contract extension through the 2026-27 season. The Kings have lost an NBA-worst nine games this season after leading in the fourth quarter with the worst one coming in Brown's final game as coach Thursday night against Detroit. Sacramento led by 10 points with less than three minutes to play only to collapse down the stretch. Jaden Ivey converted a four-point play with 3 seconds left when he made a 3-pointer in the right corner and was fouled by De’Aaron Fox. That gave the Pistons a 114-113 win, leaving the Kings in 12th place in the Western Conference. Brown has a 107-88 record in two-plus seasons in Sacramento with a winning record in both of his full seasons. Rick Adelman is the only other coach to post a winning record in a full season since the Kings moved to Sacramento Brown previously had two stints as coach in Cleveland and spent one-plus season as Lakers coach. He has a 455-304 record and has made the playoffs in seven of his nine full seasons. He won Coach of the Year twice, also getting the award in Cleveland in 2008-09. ___ AP NBA: https://apnews.com/hub/NBA Josh Dubow, The Associated Press

    SEOUL, South Korea — South Korea’s opposition-controlled National Assembly voted Friday to impeach acting President Han Duck-soo despite vehement protests by governing party lawmakers, further deepening the country’s political crisis set off by President Yoon Suk Yeol’s stunning imposition of martial law and ensuing impeachment. Han’s impeachment means he will be stripped of the powers and duties of the president until the Constitutional Court decides whether to dismiss or reinstate him. The court is already reviewing whether to uphold Yoon’s earlier impeachment. The impeachments of the country’s top two officials worsened its political turmoil, deepened economic uncertainties and hurt its international image. The single-chamber National Assembly passed Han’s impeachment motion with a 192-0 vote. Lawmakers with the governing People Power Party boycotted the vote and surrounded the podium where assembly Speaker Woo Won Shik was seated, shouting that the vote was invalid and demanding Woo’s resignation. No violence or injuries were reported. The PPP lawmakers protested after Woo called for a vote on Han’s impeachment motion after announcing its passage required a simple majority in the 300-member assembly, not a two-thirds majority as claimed by the PPP. In a statement, Han said his impeachment was regrettable but added that he respects the assembly’s decision and will suspend his duties to “not add to additional confusion and uncertainty.” He said he will wait for “a swift, wise decision” by the Constitutional Court. The deputy prime minister and finance minister, Choi Sang-mok, took over. Later Friday, Choi’s office said he instructed the military to boost its readiness to help prevent North Korea from miscalculating the situation and launching provocations. He also told the foreign ministry to inform the United States, Japan and other major partners that South Korea’s foreign policies remain unchanged. Han, who was appointed prime minister by Yoon, became acting president after the National Assembly impeached Yoon, a conservative, about two weeks ago over his short-lived Dec. 3 imposition of martial law. Get local news delivered to your inbox!NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: BurTech Acquisition Corp. (NASDAQ: BRKH ) , relating to the proposed merger with Blaize, Inc. Under the terms of the agreement, shares of BurTech Acquisition will be exchanged for shares of Blaize. ACT NOW. The Shareholder Vote is scheduled for December 10, 2024. Click here for more information https://monteverdelaw.com/case/burtech-acquisition-corp-brkh/ . It is free and there is no cost or obligation to you. Atlantic Union Bankshares Corp. (NYSE: AUB ) , relating to a proposed merger with Sandy Spring Bancorp, Inc. Under the terms of the agreement, all Sandy Spring shares will automatically be converted into the right to receive 0.900 shares of AUB, and cash in lieu of fractional shares. Click here for more information https://monteverdelaw.com/case/atlantic-union-bankshares-corp/ . It is free and there is no cost or obligation to you. Innovid Corp. (NYSE: CTV ) , relating to the proposed merger with Mediaocean LLC. Under the terms of the agreement, Mediaocean will acquire Innovid at a price of $3.15 per share of common stock. Click here for more https://monteverdelaw.com/case/innovid-corp-ctv/ . It is free and there is no cost or obligation to you. Village Bank and Trust Financial Corp. (NASDAQ: VBFC ) , relating to the proposed merger with TowneBank. Under the terms of the agreement, shareholders of Village will receive $80.25 per share in cash for each share of Village outstanding common stock. ACT NOW . The Shareholder Vote is scheduled for December 19, 2024 . Click here for more information https://monteverdelaw.com/case/village-bank-and-trust-financial-corp-vbfc/ . It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America jmonteverde@monteverdelaw.com Tel: (212) 971-1341 Attorney Advertising. (C) 2024 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( www.monteverdelaw.com ). Prior results do not guarantee a similar outcome with respect to any future matter.

    NASHVILLE, Tenn (AP) — Nico Iamaleava threw for 257 yards and four touchdowns rallying No. 7 Tennessee from a 14-point deficit within the first five minutes to rout in-state rival Vanderbilt 36-23 Saturday. “Man, it couldn't have started any worse,” Tennessee coach Josh Heupel told his Vols postgame . “And you know what? Competitive composure ... You just kept coming. That's what elite people, champions do. You just keep coming.” The Volunteers (10-2, 6-2 Southeastern Conference; No. 8 CFP) needed a big victory to impress the College Football Playoff committee enough to earn a home playoff game in December. They beat Vanderbilt (6-6, 3-5) for a sixth straight season leaving the Commodores needing to win their bowl game to post their first winning record since 2013. Better yet, the Vols rebounded from a nightmare start giving up the first 14 points by scoring 29 straight points. They led 24-17 at halftime on Iamaleava's first three TD passes. “Once they took the momentum, we kind of allowed them to have it for the rest of the game," Vanderbilt coach Clark Lea said. "And you got to credit Tennessee. I mean, obviously, they were playing for the playoffs and credit coach Heupel and his team for their winning performance.” Junior Sherrill returned the opening kickoff 100 yards for a touchdown for Vanderbilt to stun a mostly orange crowd. Dylan Sampson fumbled on the Vols’ second play from scrimmage, and Sedrick Alexanader's 4-yard TD run on a 26-yard drive put Vandy up 14-0 quickly. Then Iamaleava got Tennessee going with a 28-yard TD pass to Dont’e Thornton Jr. Tennessee got a break when Max Gilbert's 50-yard field goal bounced off the crossbar and over. Iamaleava found Thornton again on an 86-yard catch-and-run TD, then he tossed an 18-yard TD pass to Miles Kitselman just before halftime. Iamaleava capped the opening drive of the third quarter hitting Mike Matthews with a 14-yard TD pass for a 31-17 lead. The Vols added a safety by Tyre West and another Gilbert field goal. Diego Pavia threw a 31-yard TD pass to Richie Hoskins late with Vandy's 2-point conversion failing for the final margin. Tennessee didn't make a good early impression with yet another slow start. The Vols need to hope for some help to have a chance at moving up a spot or two . The big question is whether the Vols get to host a playoff game in December at Neyland Stadium where they went undefeated this season. Tennessee put together TD drives of 91 and 96 yards in the first half alone. The Vols then beat Vandy at its own game of keepaway after not even managing 10 minutes of possession in the first half. They finished with the edge in that stat outgaining Vandy 538-212. Vanderbilt had some of the best offensive success against Tennessee of any opponent this season. The Commodores had 114 yards rushing and 17 points by halftime against a defense that came in ranked sixth nationally allowing just 98.8 yards a game. The Vols had been fourth in the country giving up just 13.1 points a game having held 10 of 11 opponents under 20 points this season. But Lea said the Commodores ran just 11 plays to Tennessee's 44 after halftime. The Tennessee running back, who set the program record with 22 rushing TDs this season, didn't reach the end zone for the first time this season. Sampson finished with 178 yards rushing to reach 1,485 yards for the season, topping the school mark of 1,464 set by Travis Stephens in 2001. Tennessee waits to hear its spot in the CFP field, while Vanderbilt learns its bowl destination Dec. 8. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football.

    Global reaction to the fall of Assad ranges from jubilation to alarm

    Packers wide receiver Romeo Doubs leaves game because of concussion49ers give birthday-boy Purdy a patchwork offensive line for home finale

    CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR ), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen [email protected] 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg [email protected] -- Financial Tables Follow – SOURCE Citius Oncology, Inc.

    NEW YORK (AP) — Technology stocks are dragging down the market as Friday as Wall Street closes out a holiday-shortened week. The S&P 500 fell 1.6%, with more than 80% of stocks in the benchmark index losing ground. The benchmark index was managing to hold onto a modest gain for the week. The Dow Jones Industrial Average fell 475 points, or 1.1%, to 42,850 as of 11:35 a.m. Eastern time. The Nasdaq composite fell 2%. Technology stocks were the biggest drag on the market Friday. Semiconductor giant Nvidia slumped 2.4%. Its enormous valuation gives it an outsize influence on indexes. Other Big Tech stocks losing ground included Microsoft, with a 1.9% decline. A wide range of retailers also fell. Amazon fell 2% and Best Buy slipped 1%. The sector is being closely watched for clues on how it performed during the holiday shopping season. Energy was the only sector within the S&P 500 rising. It gained 0.4% as crude oil prices rose 1.2%. Investors don't have much in the way of corporate or economic updates to review as the market moves closer to another standout annual finish. The S&P 500 is on track for a gain of just under 25% in 2024. That would mark a second consecutive yearly gain of more than 20%, the first time that has happened since 1997-1998. The gains have been driven partly by upbeat economic data showing that consumers continued spending and the labor market remained strong. Inflation, while still high, has also been steadily easing. A report on Friday showed that sales and inventory estimates for the wholesales trade industry fell 0.2% in November, following a slight gain in October. That weaker-than-expected report follows an update on the labor market Thursday that showed unemployment benefits held steady last week. The stream of upbeat economic data and easing inflation helped prompt a reversal in the Federal Reserve's interest rate policy this year. Expectations for interest rate cuts also helped drive market gains. The central bank recently delivered its third cut to interest rates in 2024. Even though Inflation has come closer to the central bank's target of 2%, it remains stubbornly above that mark and worries about it heating up again have tempered the forecast for more interest rate cuts. Inflation concerns have added to uncertainties heading into 2025, which include the labor market’s path ahead and shifting economic policies under incoming President Donald Trump. Worries have risen that Trump’s preference for tariffs and other policies could lead to higher inflation , a bigger U.S. government debt and difficulties for global trade. Amedisys rose 4.5% after the home health care and hospice services provider agreed to extend the deadline for its sale to UnitedHealth Group. The Justice Department had sued to block the $3.3 billion deal, citing concerns he combination would hinder access to home health and hospice services in the U.S. The move to extend the deadline comes ahead of an expected shift in regulatory policy under Trump. The incoming administration is expected to have a more permissive approach to dealmaking and is less likely to raise antitrust concerns. In Asia, Japan’s benchmark index surged as the yen remained weak against the dollar. Stocks in South Korea fell after the main opposition party voted to impeach the country’s acting leader. Markets in Europe gained ground. Bond yields held relatively steady. The yield on the 10-year Treasury remained at 4.59% from late Thursday. The yield on the two-year Treasury slipped to 4.31% from 4.33% late Thursday. Wall Street will have more economic updates to look forward to next week, including reports on pending home sales and home prices. There will also be reports on U.S. construction spending and snapshots of manufacturing activity.Digital literacy: NITDA seeks education minister’s support on school curriculum

    Previous: Ph*NW e 1yx5B;w'Ae긲{nQ8 1B&ҭ
    Next: